Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials?

Alba Fiorentino, Mario Balducci, Pasquale De Bonis, Silvia Chiesa, Laura De Filippo, Annunziato Mangiola, Fiorenza De Rose, Rosa Autorino, Carla Rinaldi, Sergio Fersino, Barbara Diletto, Paolo Matteucci, Elisa Ciurlia, Vincenzo Fusco, Carmelo Anile, Vincenzo Valentini

Research output: Contribution to journalArticle

Abstract

Objectives: Age is an unfavorable prognostic factor in glioblastoma multiforme (GBM). To assess the possibility and the advantage of radiotherapy (RT) plus concomitant/sequential temozolomide (TMZ) in patients over 65 years with GBM, we analyzed 4 prospective trials in terms of compliance and outcomes. Methods: Elderly patients with histologically proven GBM, included in 4 prospective phase II studies with a Karnofsky Performance Status (KPS) >70 and a Charlson Comorbidity Index (CCI) 70 and CCI

Original languageEnglish
Pages (from-to)23-27
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume38
Issue number1
DOIs
Publication statusPublished - Feb 2 2015

    Fingerprint

Keywords

  • chemoradiation
  • comorbidity
  • elderly
  • Glioblastoma
  • temozolomide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Fiorentino, A., Balducci, M., De Bonis, P., Chiesa, S., De Filippo, L., Mangiola, A., De Rose, F., Autorino, R., Rinaldi, C., Fersino, S., Diletto, B., Matteucci, P., Ciurlia, E., Fusco, V., Anile, C., & Valentini, V. (2015). Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials? American Journal of Clinical Oncology: Cancer Clinical Trials, 38(1), 23-27. https://doi.org/10.1097/COC.0b013e3182868ea2